BioSpace News Archive

GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, announced Mostafa Ronaghi, PhD, joined the GRAIL Board of Directors.

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Monday, May 11, 2020.

DURECT Corporation announced that it will report first quarter 2020 financial results and host a conference call after the market close on Monday, May 11, 2020.

Veeva Systems (NYSE:VEEV) will announce financial results for its first quarter which ended April 30, 2020 after market close on May 28, 2020.

Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report first quarter 2020 financial results on Thursday, May 7, 2020, before the market opens.

As part of the medical technology industry’s multi-front battle to combat the coronavirus (COVID-19) pandemic, today the Advanced Medical Technology Association (AdvaMed) announced the launch of a new platform (www.VentConnect.org) to connect ventilator companies with component suppliers to help quickly scale production and distribution of these vital devices.

Moleculin Biotech, Inc.,, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced securities of the Company have been placed in a temporary trading halt following notification by the US Securities and Exchange Commission.

Abstracts originally accepted for 2020 Digestive Disease Week Conference – to be published online

Company to increase access to critical mental health services for front-line workers impacted by COVID-19 with over $1 million in charitable support

Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the company developing a new class of broad-spectrum synthetic antibiotics, today announced positive efficacy showing significant antibacterial activity against Neisseria gonorrhoeae bacteria in mice treated with its lead compound RECCE® 327.